Literature DB >> 22241325

Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma.

C L Donohoe1, S L Doyle, S McGarrigle, M C Cathcart, E Daly, A O'Grady, J Lysaght, G P Pidgeon, J V Reynolds.   

Abstract

BACKGROUND: Epidemiological studies have linked obesity with many cancers. The insulin-like growth factor (IGF) 1 axis may be an important mediator in obesity-associated cancer. This study examined the relationship between IGF-1 and its receptor (IGF-1R) in oesophageal adenocarcinoma, a cancer strongly linked to obesity.
METHODS: Patients with oesophageal adenocarcinoma considered suitable for attempted curative treatment were studied. Visceral adiposity was defined by waist circumference or visceral fat area. Free and total IGF-1 in serum were measured by enzyme-linked immunosorbent assay. Quantitative polymerase chain resection was used to determine mRNA expression of IGF-1 and IGF-1R in resected tumour samples. IGF-1R expression in tissue microarrays (TMAs) was quantified by immunohistochemistry.
RESULTS: A total of 220 patients were studied. Total and free IGF-1 levels were significantly increased in the serum of viscerally obese patients. Gene expression analysis revealed a significant association between obesity status and both IGF-1R (P = 0·021) and IGF-1 (P = 0·031) in tumours. TMA analysis demonstrated that IGF-1R expression in resected tumours was significantly higher in viscerally obese patients than in those of normal weight (P = 0·023). Disease-specific survival was longer in patients with negative IGF-1R expression than in those with IGF-1R-positive tumours (median 60·0 versus 23·4 months; P = 0·027).
CONCLUSION: This study highlighted the association of the IGF axis with visceral obesity, and a potential impact on the biology of oesophageal adenocarcinoma through its receptor. Targeting the IGF axis may have a rationale in future studies.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241325     DOI: 10.1002/bjs.8658

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  17 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

2.  The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Authors:  Yasushi Adachi; Hirokazu Ohashi; Arisa Imsumran; Hiroyuki Yamamoto; Yasutaka Matsunaga; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Yasushi Sasaki; Yoshiaki Arimura; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2013-09-13

Review 3.  The role of obesity in gastrointestinal cancer: evidence and opinion.

Authors:  Claire L Donohoe; Naoimh J O'Farrell; Suzanne L Doyle; John V Reynolds
Journal:  Therap Adv Gastroenterol       Date:  2014-01       Impact factor: 4.409

Review 4.  Mechanisms of obesity-induced gastrointestinal neoplasia.

Authors:  José O Alemán; Peter R Holt; Leonardo H Eusebi; Luigi Ricciardiello; Kavish Patidar; Arun J Sanyal
Journal:  Gastroenterology       Date:  2013-12-06       Impact factor: 22.682

5.  Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.

Authors:  Jiahuang Liu; Xiangming Che; Jiangtao You; Guangjian Zhang; Rui Zhao; Junke Fu; Haijun Li
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

6.  Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study.

Authors:  Cadman L Leggett; Eric M Nelsen; Jianmin Tian; Cathy B Schleck; Alan R Zinsmeister; Kelly T Dunagan; G Richard Locke; Kenneth K Wang; Nicholas J Talley; Prasad G Iyer
Journal:  Mayo Clin Proc       Date:  2013-02       Impact factor: 7.616

7.  Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis.

Authors:  Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

8.  Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Shruti G Dighe; Jianhong Chen; Li Yan; Qianchuan He; Puya Gharahkhani; Lynn Onstad; David M Levine; Claire Palles; Weimin Ye; Marilie D Gammon; Prasad G Iyer; Lesley A Anderson; Geoffrey Liu; Anna H Wu; James Y Dai; Wong-Ho Chow; Harvey A Risch; Jesper Lagergren; Nicholas J Shaheen; Leslie Bernstein; Douglas A Corley; Hans Prenen; John deCaestecker; David MacDonald; Paul Moayyedi; Hugh Barr; Sharon B Love; Laura Chegwidden; Stephen Attwood; Peter Watson; Rebecca Harrison; Katja Ott; Susanne Moebus; Marino Venerito; Hauke Lang; Rupert Mayershofer; Michael Knapp; Lothar Veits; Christian Gerges; Josef Weismüller; Ines Gockel; Yogesh Vashist; Markus M Nöthen; Jakob R Izbicki; Hendrik Manner; Horst Neuhaus; Thomas Rösch; Anne C Böhmer; Arnulf H Hölscher; Mario Anders; Oliver Pech; Brigitte Schumacher; Claudia Schmidt; Thomas Schmidt; Tania Noder; Dietmar Lorenz; Michael Vieth; Andrea May; Timo Hess; Nicole Kreuser; Jessica Becker; Christian Ell; Christine B Ambrosone; Kirsten B Moysich; Stuart MacGregor; Ian Tomlinson; David C Whiteman; Janusz Jankowski; Johannes Schumacher; Thomas L Vaughan; Margaret M Madeleine; Laura J Hardie; Matthew F Buas
Journal:  Carcinogenesis       Date:  2021-04-17       Impact factor: 4.944

Review 9.  Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.

Authors:  Leo Alexandre; Elizabeth Long; Ian Lp Beales
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

10.  A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.

Authors:  Rosalyne L Westley; Felicity E B May
Journal:  Int J Endocrinol       Date:  2013-07-31       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.